Specific Ocular Findings Leading to the Diagnosis of Early-Onset Neurofibromatosis Type 2
Keywords:
Neurofibromatosis, Retinal hamartoma, Pediatric ophthalmology, Optic nerve sheath meningioma, Neurofibromatosis Type 2, Pediatric neurofibromatosisAbstract
Background: Neurofibromatosis type 2 (NF2) genetic disorder primarily characterized by the central nervous
system tumors, including intracranial schwannomas and meningiomas.Diagnosis is often delayed due to variable
presentations, especially in pediatric patients where ophthalmologic abnormalities may be the earliest sign.
Case Presentation: A 4-year-old boy referred for ocular evaluation due to multiple café-au-lait macules.
Initial examination revealed reduced visual acuity, bilateral iris mammillation, and left retinal hamartoma, raising
suspicion of NF2. Despite glasses being prescribed, the patient was lost to follow-up and returned at age 8 with left eye visual deterioration. Subsequent examination identified a flame-like epiretinal membrane (ERM) in the right eye and
a combined hamartoma of the retina and retinal pigment epithelium (CHRRPE) in the left eye. Magnetic Resonance
Imaging (MRI) confirmed multiple cranial nerve schwannomas and a left optic nerve sheath meningioma (ONSM), confirming the NF2 diagnosis at age 10.
Discussion: Pediatric NF2 can present with distinctive ocular findings: cortical cataracts, ERMs, CHRRPE,
and ONSMs, which may precede neurological symptoms. Early recognition of NF2 ocular signs is crucial for timely
diagnosis and management, potentially reducing morbidity.
Conclusion: This case highlights importance of thorough ophthalmologic evaluation in NF2 children. Early
diagnosis can guide appropriate multidisciplinary management, improving prognosis in pediatric NF2 patients.
References
Wishart JH. Case of Tumours in the Skull, Dura Mater, and Brain. Edinb Med Surg J. Jul 1 1822;18(72):393-397.
Antinheimo J, Sankila R, Carpen O, et al. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology. Jan 11 2000;54(1):71-6. doi:10.1212/wnl.54.1.71
Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. Feb 2010;152A(2):327-32. doi:10.1002/ajmg.a.33139
Evans DG, Moran A, King A, et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol. Jan 2005;26(1):93-7. doi:10.1097/00129492-200501000-00016
Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis. Jun 19 2009;4:16. doi:10.1186/1750-1172-4-16
Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med. Aug 1992;84(304):603-18.
Halliday D, Emmanouil B, Pretorius P, et al. Genetic Severity Score predicts clinical phenotype in NF2. J Med Genet. Oct 2017;54(10):657-664. doi:10.1136/jmedgenet-2017-104519
Coy S, Rashid R, Stemmer-Rachamimov A, et al. Correction to: An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathol. Apr 2020;139(4):667. doi:10.1007/s00401-019-02044-6
Coy S, Rashid R, Stemmer-Rachamimov A, et al. An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathol. Apr 2020;139(4):643-665. doi:10.1007/s00401-019-02029-5
Evans DG, King AT, Bowers NL, et al. Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing. Genet Med. Jul 2019;21(7):1525-1533. doi:10.1038/s41436-018-0384-y
Gugel I, Grimm F, Teuber C, et al. Presenting symptoms in children with neurofibromatosis type 2. Childs Nerv Syst. Oct 2020;36(10):2463-2470. doi:10.1007/s00381-020-04729-w
Anand G, Vasallo G, Spanou M, et al. Diagnosis of sporadic neurofibromatosis type 2 in the paediatric population. Arch Dis Child. May 2018;103(5):463-469. doi:10.1136/archdischild-2017-313154
Matsuo M, Ohno K, Ohtsuka F. Characterization of early onset neurofibromatosis type 2. Brain Dev. Feb 2014;36(2):148-52. doi:10.1016/j.braindev.2013.01.007
Ruggieri M, Iannetti P, Polizzi A, et al. Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. Neuropediatrics. Feb 2005;36(1):21-34. doi:10.1055/s-2005-837581
McLaughlin ME, Pepin SM, Maccollin M, et al. Ocular pathologic findings of neurofibromatosis type 2. Arch Ophthalmol. Mar 2007;125(3):389-94. doi:10.1001/archopht.125.3.389
Chan CC, Koch CA, Kaiser-Kupfer MI, et al. Loss of heterozygosity for the NF2 gene in retinal and optic nerve lesions of patients with neurofibromatosis 2. J Pathol. Sep 2002;198(1):14-20. doi:10.1002/path.1174
Kang HM, Koh HJ, Chung EJ. Spectral-domain optical coherence tomography of combined hamartoma of the retina and retinal pigment epithelium in neurofibromatosis. Korean J Ophthalmol. Feb 2013;27(1):68-71. doi:10.3341/kjo.2013.27.1.68
Waisberg V, Rodrigues LO, Nehemy MB, et al. Spectral-Domain Optical Coherence Tomography Findings in Neurofibromatosis Type 2. Invest Ophthalmol Vis Sci. Jul 1 2016;57(9):OCT262-7. doi:10.1167/iovs.15-18919
Sisk RA, Berrocal AM, Schefler AC, et al. Epiretinal membranes indicate a severe phenotype of neurofibromatosis type 2. Retina. Apr 2010;30(4 Suppl):S51-8. doi:10.1097/IAE.0b013e3181dc58bf
Rishi P, Hirawat RS, Verma A. Association of bilateral, multiple presumed retinal astrocytic proliferations with combined hamartoma of retina and retinal pigment epithelium in a 9-year-old male child with neurofibromatosis type 2. Indian J Ophthalmol. Nov 2016;64(11):850-852. doi:10.4103/0301-4738.195609
Martin K, Rossi V, Ferrucci S, et al. Retinal astrocytic hamartoma. Optometry. May 2010;81(5):221-33. doi:10.1016/j.optm.2009.12.009
Chin EK, Almeida DR, Boldt HC. Combined Hamartoma of the Retina and Retinal Pigment Epithelium Leading to the Diagnosis of Neurofibromatosis Type 2. JAMA Ophthalmol. Sep 2015;133(9):e151289. doi:10.1001/jamaophthalmol.2015.1289
Starosta DA, Lorenz B. [Retinal Astrocytic Hamartoma in Neurofibromatosis Type 2 - Metaanalysis and a Case Report]. Klin Monbl Augenheilkd. Mar 2018;235(3):290-300. Retinale astrozytäre Hamartome bei Neurofibromatose Typ 2 – Metaanalyse und Fallbericht. doi:10.1055/a-0583-0291
Levin LA, Jakobiec FA. Optic nerve tumors of childhood: a decision-analytical approach to their diagnosis. Int Ophthalmol Clin. Winter 1992;32(1):223-40. doi:10.1097/00004397-199203210-00017
Bosch MM, Wichmann WW, Boltshauser E, Landau K. Optic nerve sheath meningiomas in patients with neurofibromatosis type 2. Arch Ophthalmol. 2006;124(3):379-385. doi:10.1001/archopht.124.3.379.
Feucht M, Griffiths B, Niemuller I, et al. Neurofibromatosis 2 leads to higher incidence of strabismological and neuro-ophthalmological disorders. Acta Ophthalmol. Dec 2008;86(8):882-6. doi:10.1111/j.1600-0420.2007.01088.x
Evans DG, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child. Dec 1999;81(6):496-9. doi:10.1136/adc.81.6.496
Ardern-Holmes S, Fisher G, North K. Neurofibromatosis Type 2:Presentation, Major Complications, and Management, With a Focus on the Pediatric Age Group. Journal of Child Neurology. 2017;32(1):9-22. doi:10.1177/0883073816666736
Downloads
Published
Versions
- 2025-12-26 (2)
- 2025-12-26 (1)
Issue
Section
License
Copyright (c) 2025 The THAI Journal of OPHTHALMOLOGY

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Thai Journal of Ophthalmology (TJO) is a peer-reviewed, scientific journal published biannually for the Royal College of Ophthalmologists of Thailand. The objectives of the journal is to provide up to date scientific knowledge in the field of ophthalmology, provide ophthalmologists with continuing education, promote cooperation, and sharing of opinion among readers.
The copyright of the published article belongs to the Thai Journal of Ophthalmology. However the content, ideas and the opinions in the article are from the author(s). The editorial board does not have to agree with the authors’ ideas and opinions.
The authors or readers may contact the editorial board via email at admin@rcopt.org.